Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1998 Jun 15;101(12):2842–2850. doi: 10.1172/JCI1130

Cisplatin-induced apoptosis in rat dorsal root ganglion neurons is associated with attempted entry into the cell cycle.

J S Gill 1, A J Windebank 1
PMCID: PMC508875  PMID: 9637718

Abstract

Platinum compounds induce apoptosis in malignant cells and are used extensively in the treatment of cancer. Total dose is limited by development of a sensory neuropathy. We now demonstrate that when rats are administered cisplatin (2 mg/kg i.p. for 5 d), primary sensory neurons in the dorsal root ganglion die by apoptosis. This was reproduced by exposure of dorsal root ganglion neurons and PC12 cells to cisplatin (3 microg/ml) in vitro. Apoptosis was confirmed by electron microscopy, DNA laddering, and inhibition by the caspase inhibitor z-VAD.fmk (100 microM). Cell death in vitro was preceded by upregulation of cyclin D1, cdk4, and increased phosphorylation of retinoblastoma protein; all are indicators of cell cycle advancement. The level of p16(INK4a), an endogenous inhibitor of the cyclin D1/cdk4 complex decreased. Exposure of PC12 cells and dorsal root ganglion neurons to increased levels of nerve growth factor (100 ng/ ml) prevented both apoptosis and upregulation of the cell cycle markers. Cancer cells without nerve growth factor receptors (gp140TrkA) were not protected by the neurotrophin. This indicated that cisplatin may kill cancer cells and neurons by a similar mechanism. In postmitotic neurons, this involves an attempt to re-enter the cell cycle resulting in apoptosis which is specifically prevented by nerve growth factor.

Full Text

The Full Text of this article is available as a PDF (5.7 MB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allday M. J., Inman G. J., Crawford D. H., Farrell P. J. DNA damage in human B cells can induce apoptosis, proceeding from G1/S when p53 is transactivation competent and G2/M when it is transactivation defective. EMBO J. 1995 Oct 16;14(20):4994–5005. doi: 10.1002/j.1460-2075.1995.tb00182.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Almasan A., Linke S. P., Paulson T. G., Huang L. C., Wahl G. M. Genetic instability as a consequence of inappropriate entry into and progression through S-phase. Cancer Metastasis Rev. 1995 Mar;14(1):59–73. doi: 10.1007/BF00690212. [DOI] [PubMed] [Google Scholar]
  3. Almasan A., Yin Y., Kelly R. E., Lee E. Y., Bradley A., Li W., Bertino J. R., Wahl G. M. Deficiency of retinoblastoma protein leads to inappropriate S-phase entry, activation of E2F-responsive genes, and apoptosis. Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5436–5440. doi: 10.1073/pnas.92.12.5436. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Apfel S. C., Arezzo J. C., Lipson L., Kessler J. A. Nerve growth factor prevents experimental cisplatin neuropathy. Ann Neurol. 1992 Jan;31(1):76–80. doi: 10.1002/ana.410310114. [DOI] [PubMed] [Google Scholar]
  5. Barajon I., Bersani M., Quartu M., Del Fiacco M., Cavaletti G., Holst J. J., Tredici G. Neuropeptides and morphological changes in cisplatin-induced dorsal root ganglion neuronopathy. Exp Neurol. 1996 Mar;138(1):93–104. doi: 10.1006/exnr.1996.0050. [DOI] [PubMed] [Google Scholar]
  6. Batistatou A., Greene L. A. Internucleosomal DNA cleavage and neuronal cell survival/death. J Cell Biol. 1993 Aug;122(3):523–532. doi: 10.1083/jcb.122.3.523. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Boekelheide K., Arcila M. E., Eveleth J. cis-diamminedichloroplatinum (II) (cisplatin) alters microtubule assembly dynamics. Toxicol Appl Pharmacol. 1992 Sep;116(1):146–151. doi: 10.1016/0041-008x(92)90156-m. [DOI] [PubMed] [Google Scholar]
  8. Capizzi R. L. Protection of normal tissues from the cytotoxic effects of chemotherapy by amifostine (Ethyol): clinical experiences. Semin Oncol. 1994 Oct;21(5 Suppl 11):8–15. [PubMed] [Google Scholar]
  9. Cascinu S., Cordella L., Del Ferro E., Fronzoni M., Catalano G. Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: a randomized double-blind placebo-controlled trial. J Clin Oncol. 1995 Jan;13(1):26–32. doi: 10.1200/JCO.1995.13.1.26. [DOI] [PubMed] [Google Scholar]
  10. Cavaletti G., Bogliun G., Marzorati L., Tredici G., Colombo N., Parma G., Miceli M. D. Long-term peripheral neurotoxicity of cisplatin in patients with successfully treated epithelial ovarian cancer. Anticancer Res. 1994 May-Jun;14(3B):1287–1292. [PubMed] [Google Scholar]
  11. Cavaletti G., Minoia C., Schieppati M., Tredici G. Protective effects of glutathione on cisplatin neurotoxicity in rats. Int J Radiat Oncol Biol Phys. 1994 Jul 1;29(4):771–776. doi: 10.1016/0360-3016(94)90565-7. [DOI] [PubMed] [Google Scholar]
  12. Cavaletti G., Tredici G., Marmiroli P., Fabbrica D., Braga M. Off-treatment course of cisplatin-induced dorsal root ganglia neuronopathy in rats. In Vivo. 1994 May-Jun;8(3):313–316. [PubMed] [Google Scholar]
  13. Cece R., Petruccioli M. G., Cavaletti G., Barajon I., Tredici G. An ultrastructural study of neuronal changes in dorsal root ganglia (DRG) of rats after chronic cisplatin administrations. Histol Histopathol. 1995 Oct;10(4):837–845. [PubMed] [Google Scholar]
  14. Cowan J. D., Kies M. S., Roth J. L., Joyce R. P. Nerve conduction studies in patients treated with cis-diamminedichloroplatinum(II): a preliminary report. Cancer Treat Rep. 1980 Oct-Nov;64(10-11):1119–1122. [PubMed] [Google Scholar]
  15. De Luca A., Esposito V., Baldi A., Giordano A. The retinoblastoma gene family and its role in proliferation, differentiation and development. Histol Histopathol. 1996 Oct;11(4):1029–1034. [PubMed] [Google Scholar]
  16. DeCaprio J. A., Furukawa Y., Ajchenbaum F., Griffin J. D., Livingston D. M. The retinoblastoma-susceptibility gene product becomes phosphorylated in multiple stages during cell cycle entry and progression. Proc Natl Acad Sci U S A. 1992 Mar 1;89(5):1795–1798. doi: 10.1073/pnas.89.5.1795. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Dowdy S. F., Hinds P. W., Louie K., Reed S. I., Arnold A., Weinberg R. A. Physical interaction of the retinoblastoma protein with human D cyclins. Cell. 1993 May 7;73(3):499–511. doi: 10.1016/0092-8674(93)90137-f. [DOI] [PubMed] [Google Scholar]
  18. Elledge S. J., Harper J. W. Cdk inhibitors: on the threshold of checkpoints and development. Curr Opin Cell Biol. 1994 Dec;6(6):847–852. doi: 10.1016/0955-0674(94)90055-8. [DOI] [PubMed] [Google Scholar]
  19. Enoch T., Norbury C. Cellular responses to DNA damage: cell-cycle checkpoints, apoptosis and the roles of p53 and ATM. Trends Biochem Sci. 1995 Oct;20(10):426–430. doi: 10.1016/s0968-0004(00)89093-3. [DOI] [PubMed] [Google Scholar]
  20. Farinelli S. E., Greene L. A. Cell cycle blockers mimosine, ciclopirox, and deferoxamine prevent the death of PC12 cells and postmitotic sympathetic neurons after removal of trophic support. J Neurosci. 1996 Feb 1;16(3):1150–1162. doi: 10.1523/JNEUROSCI.16-03-01150.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Ferrari G., Yan C. Y., Greene L. A. N-acetylcysteine (D- and L-stereoisomers) prevents apoptotic death of neuronal cells. J Neurosci. 1995 Apr;15(4):2857–2866. doi: 10.1523/JNEUROSCI.15-04-02857.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Fisher R. P. CDKs and cyclins in transition(s). Curr Opin Genet Dev. 1997 Feb;7(1):32–38. doi: 10.1016/s0959-437x(97)80106-2. [DOI] [PubMed] [Google Scholar]
  23. Freeman R. S., Estus S., Johnson E. M., Jr Analysis of cell cycle-related gene expression in postmitotic neurons: selective induction of Cyclin D1 during programmed cell death. Neuron. 1994 Feb;12(2):343–355. doi: 10.1016/0896-6273(94)90276-3. [DOI] [PubMed] [Google Scholar]
  24. Fu K. K., Kai E. F., Leung C. K. Cisplatin neuropathy: a prospective clinical and electrophysiological study in Chinese patients with ovarian carcinoma. J Clin Pharm Ther. 1995 Jun;20(3):167–172. doi: 10.1111/j.1365-2710.1995.tb00644.x. [DOI] [PubMed] [Google Scholar]
  25. Gao W. Q., Dybdal N., Shinsky N., Murnane A., Schmelzer C., Siegel M., Keller G., Hefti F., Phillips H. S., Winslow J. W. Neurotrophin-3 reverses experimental cisplatin-induced peripheral sensory neuropathy. Ann Neurol. 1995 Jul;38(1):30–37. doi: 10.1002/ana.410380108. [DOI] [PubMed] [Google Scholar]
  26. Gerritsen van der Hoop R., Hamers F. P., Neijt J. P., Veldman H., Gispen W. H., Jennekens F. G. Protection against cisplatin induced neurotoxicity by ORG 2766: histological and electrophysiological evidence. J Neurol Sci. 1994 Nov;126(2):109–115. doi: 10.1016/0022-510x(94)90259-3. [DOI] [PubMed] [Google Scholar]
  27. Gill J. S., Connolly D. C., McManus M. J., Maihle N. J., Windebank A. J. Suramin induces phosphorylation of the high-affinity nerve growth factor receptor in PC12 cells and dorsal root ganglion neurons. J Neurochem. 1996 Mar;66(3):963–972. doi: 10.1046/j.1471-4159.1996.66030963.x. [DOI] [PubMed] [Google Scholar]
  28. Giordano A., Kaiser H. E. The retinoblastoma gene: its role in cell cycle and cancer. In Vivo. 1996 Mar-Apr;10(2):223–227. [PubMed] [Google Scholar]
  29. Gispen W. H., Hamers F. P., Vecht C. J., Jennekens F. G., Neyt J. P. ACTH/MSH like peptides in the treatment of cisplatin neuropathy. J Steroid Biochem Mol Biol. 1992 Sep;43(1-3):179–183. doi: 10.1016/0960-0760(92)90205-w. [DOI] [PubMed] [Google Scholar]
  30. Gregg R. W., Molepo J. M., Monpetit V. J., Mikael N. Z., Redmond D., Gadia M., Stewart D. J. Cisplatin neurotoxicity: the relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity. J Clin Oncol. 1992 May;10(5):795–803. doi: 10.1200/JCO.1992.10.5.795. [DOI] [PubMed] [Google Scholar]
  31. Grunberg S. M., Sonka S., Stevenson L. L., Muggia F. M. Progressive paresthesias after cessation of therapy with very high-dose cisplatin. Cancer Chemother Pharmacol. 1989;25(1):62–64. doi: 10.1007/BF00694340. [DOI] [PubMed] [Google Scholar]
  32. Hamers F. P., Brakkee J. H., Cavalletti E., Tedeschi M., Marmonti L., Pezzoni G., Neijt J. P., Gispen W. H. Reduced glutathione protects against cisplatin-induced neurotoxicity in rats. Cancer Res. 1993 Feb 1;53(3):544–549. [PubMed] [Google Scholar]
  33. Hatakeyama M., Herrera R. A., Makela T., Dowdy S. F., Jacks T., Weinberg R. A. The cancer cell and the cell cycle clock. Cold Spring Harb Symp Quant Biol. 1994;59:1–10. doi: 10.1101/sqb.1994.059.01.003. [DOI] [PubMed] [Google Scholar]
  34. Hayakawa K., Sobue G., Itoh T., Mitsuma T. Nerve growth factor prevents neurotoxic effects of cisplatin, vincristine and taxol, on adult rat sympathetic ganglion explants in vitro. Life Sci. 1994;55(7):519–525. doi: 10.1016/0024-3205(94)00744-6. [DOI] [PubMed] [Google Scholar]
  35. Hengst L., Dulic V., Slingerland J. M., Lees E., Reed S. I. A cell cycle-regulated inhibitor of cyclin-dependent kinases. Proc Natl Acad Sci U S A. 1994 Jun 7;91(12):5291–5295. doi: 10.1073/pnas.91.12.5291. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Hinds P. W., Dowdy S. F., Eaton E. N., Arnold A., Weinberg R. A. Function of a human cyclin gene as an oncogene. Proc Natl Acad Sci U S A. 1994 Jan 18;91(2):709–713. doi: 10.1073/pnas.91.2.709. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Hol E. M., Gispen W. H., Bär P. R. ACTH-related peptides: receptors and signal transduction systems involved in their neurotrophic and neuroprotective actions. Peptides. 1995;16(5):979–993. doi: 10.1016/0196-9781(95)00017-e. [DOI] [PubMed] [Google Scholar]
  38. Huang H., Zhu L., Reid B. R., Drobny G. P., Hopkins P. B. Solution structure of a cisplatin-induced DNA interstrand cross-link. Science. 1995 Dec 15;270(5243):1842–1845. doi: 10.1126/science.270.5243.1842. [DOI] [PubMed] [Google Scholar]
  39. Jayadev S., Liu B., Bielawska A. E., Lee J. Y., Nazaire F., Pushkareva MYu, Obeid L. M., Hannun Y. A. Role for ceramide in cell cycle arrest. J Biol Chem. 1995 Feb 3;270(5):2047–2052. doi: 10.1074/jbc.270.5.2047. [DOI] [PubMed] [Google Scholar]
  40. Konings P. N., Makkink W. K., van Delft A. M., Ruigt G. S. Reversal by NGF of cytostatic drug-induced reduction of neurite outgrowth in rat dorsal root ganglia in vitro. Brain Res. 1994 Mar 21;640(1-2):195–204. doi: 10.1016/0006-8993(94)91873-2. [DOI] [PubMed] [Google Scholar]
  41. Kranenburg O., van der Eb A. J., Zantema A. Cyclin D1 is an essential mediator of apoptotic neuronal cell death. EMBO J. 1996 Jan 2;15(1):46–54. [PMC free article] [PubMed] [Google Scholar]
  42. Krarup-Hansen A., Fugleholm K., Helweg-Larsen S., Hauge E. N., Schmalbruch H., Trojaborg W., Krarup C. Examination of distal involvement in cisplatin-induced neuropathy in man. An electrophysiological and histological study with particular reference to touch receptor function. Brain. 1993 Oct;116(Pt 5):1017–1041. doi: 10.1093/brain/116.5.1017. [DOI] [PubMed] [Google Scholar]
  43. Lee E. Y., Hu N., Yuan S. S., Cox L. A., Bradley A., Lee W. H., Herrup K. Dual roles of the retinoblastoma protein in cell cycle regulation and neuron differentiation. Genes Dev. 1994 Sep 1;8(17):2008–2021. doi: 10.1101/gad.8.17.2008. [DOI] [PubMed] [Google Scholar]
  44. Lees J. A., Buchkovich K. J., Marshak D. R., Anderson C. W., Harlow E. The retinoblastoma protein is phosphorylated on multiple sites by human cdc2. EMBO J. 1991 Dec;10(13):4279–4290. doi: 10.1002/j.1460-2075.1991.tb05006.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Lucidi-Phillipi C. A., Clary D. O., Reichardt L. F., Gage F. H. TrkA activation is sufficient to rescue axotomized cholinergic neurons. Neuron. 1996 Mar;16(3):653–663. doi: 10.1016/s0896-6273(00)80084-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Lévi F., Zidani R., Misset J. L. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. International Organization for Cancer Chronotherapy. Lancet. 1997 Sep 6;350(9079):681–686. doi: 10.1016/s0140-6736(97)03358-8. [DOI] [PubMed] [Google Scholar]
  47. Machover D., Diaz-Rubio E., de Gramont A., Schilf A., Gastiaburu J. J., Brienza S., Itzhaki M., Metzger G., N'Daw D., Vignoud J. Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol. 1996 Jan;7(1):95–98. doi: 10.1093/oxfordjournals.annonc.a010489. [DOI] [PubMed] [Google Scholar]
  48. Malgrange B., Delrée P., Rigo J. M., Baron H., Moonen G. Image analysis of neuritic regeneration by adult rat dorsal root ganglion neurons in culture: quantification of the neurotoxicity of anticancer agents and of its prevention by nerve growth factor or basic fibroblast growth factor but not brain-derived neurotrophic factor or neurotrophin-3. J Neurosci Methods. 1994 Jul;53(1):111–122. doi: 10.1016/0165-0270(94)90151-1. [DOI] [PubMed] [Google Scholar]
  49. McKeage M. J. Comparative adverse effect profiles of platinum drugs. Drug Saf. 1995 Oct;13(4):228–244. doi: 10.2165/00002018-199513040-00003. [DOI] [PubMed] [Google Scholar]
  50. Mollman J. E. Cisplatin neurotoxicity. N Engl J Med. 1990 Jan 11;322(2):126–127. doi: 10.1056/NEJM199001113220210. [DOI] [PubMed] [Google Scholar]
  51. Mollman J. E., Hogan W. M., Glover D. J., McCluskey L. F. Unusual presentation of cis-platinum neuropathy. Neurology. 1988 Mar;38(3):488–490. doi: 10.1212/wnl.38.3.488. [DOI] [PubMed] [Google Scholar]
  52. Motokura T., Arnold A. Cyclin D and oncogenesis. Curr Opin Genet Dev. 1993 Feb;3(1):5–10. doi: 10.1016/s0959-437x(05)80334-x. [DOI] [PubMed] [Google Scholar]
  53. Nicholson D. W., Ali A., Thornberry N. A., Vaillancourt J. P., Ding C. K., Gallant M., Gareau Y., Griffin P. R., Labelle M., Lazebnik Y. A. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature. 1995 Jul 6;376(6535):37–43. doi: 10.1038/376037a0. [DOI] [PubMed] [Google Scholar]
  54. Nobori T., Miura K., Wu D. J., Lois A., Takabayashi K., Carson D. A. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature. 1994 Apr 21;368(6473):753–756. doi: 10.1038/368753a0. [DOI] [PubMed] [Google Scholar]
  55. Ozols R. F., Ostchega Y., Myers C. E., Young R. C. High-dose cisplatin in hypertonic saline in refractory ovarian cancer. J Clin Oncol. 1985 Sep;3(9):1246–1250. doi: 10.1200/JCO.1985.3.9.1246. [DOI] [PubMed] [Google Scholar]
  56. Park D. S., Farinelli S. E., Greene L. A. Inhibitors of cyclin-dependent kinases promote survival of post-mitotic neuronally differentiated PC12 cells and sympathetic neurons. J Biol Chem. 1996 Apr 5;271(14):8161–8169. doi: 10.1074/jbc.271.14.8161. [DOI] [PubMed] [Google Scholar]
  57. Park D. S., Levine B., Ferrari G., Greene L. A. Cyclin dependent kinase inhibitors and dominant negative cyclin dependent kinase 4 and 6 promote survival of NGF-deprived sympathetic neurons. J Neurosci. 1997 Dec 1;17(23):8975–8983. doi: 10.1523/JNEUROSCI.17-23-08975.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  58. Powell S. N., Abraham E. H. The biology of radioresistance: similarities, differences and interactions with drug resistance. Cytotechnology. 1993;12(1-3):325–345. doi: 10.1007/BF00744671. [DOI] [PubMed] [Google Scholar]
  59. Roelofs R. I., Hrushesky W., Rogin J., Rosenberg L. Peripheral sensory neuropathy and cisplatin chemotherapy. Neurology. 1984 Jul;34(7):934–938. doi: 10.1212/wnl.34.7.934. [DOI] [PubMed] [Google Scholar]
  60. Russell J. W., Windebank A. J., McNiven M. A., Brat D. J., Brimijoin W. S. Effect of cisplatin and ACTH4-9 on neural transport in cisplatin induced neurotoxicity. Brain Res. 1995 Apr 10;676(2):258–267. doi: 10.1016/0006-8993(95)00100-5. [DOI] [PubMed] [Google Scholar]
  61. Schmidt Y., Unger J. W., Bartke I., Reiter R. Effect of nerve growth factor on peptide neurons in dorsal root ganglia after taxol or cisplatin treatment and in diabetic (db/db) mice. Exp Neurol. 1995 Mar;132(1):16–23. doi: 10.1016/0014-4886(95)90054-3. [DOI] [PubMed] [Google Scholar]
  62. Sherr C. J. D-type cyclins. Trends Biochem Sci. 1995 May;20(5):187–190. doi: 10.1016/s0968-0004(00)89005-2. [DOI] [PubMed] [Google Scholar]
  63. Sherr C. J., Roberts J. M. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev. 1995 May 15;9(10):1149–1163. doi: 10.1101/gad.9.10.1149. [DOI] [PubMed] [Google Scholar]
  64. Siddiqui N., Boddy A. V., Thomas H. D., Bailey N. P., Robson L., Lind M. J., Calvert A. H. A clinical and pharmacokinetic study of the combination of carboplatin and paclitaxel for epithelial ovarian cancer. Br J Cancer. 1997;75(2):287–294. doi: 10.1038/bjc.1997.47. [DOI] [PMC free article] [PubMed] [Google Scholar]
  65. Sidle A., Palaty C., Dirks P., Wiggan O., Kiess M., Gill R. M., Wong A. K., Hamel P. A. Activity of the retinoblastoma family proteins, pRB, p107, and p130, during cellular proliferation and differentiation. Crit Rev Biochem Mol Biol. 1996 Jun;31(3):237–271. doi: 10.3109/10409239609106585. [DOI] [PubMed] [Google Scholar]
  66. Thompson S. W., Davis L. E., Kornfeld M., Hilgers R. D., Standefer J. C. Cisplatin neuropathy. Clinical, electrophysiologic, morphologic, and toxicologic studies. Cancer. 1984 Oct 1;54(7):1269–1275. doi: 10.1002/1097-0142(19841001)54:7<1269::aid-cncr2820540707>3.0.co;2-9. [DOI] [PubMed] [Google Scholar]
  67. Tomiwa K., Nolan C., Cavanagh J. B. The effects of cisplatin on rat spinal ganglia: a study by light and electron microscopy and by morphometry. Acta Neuropathol. 1986;69(3-4):295–308. doi: 10.1007/BF00688308. [DOI] [PubMed] [Google Scholar]
  68. Tredici G., Cavaletti G., Petruccioli M. G., Fabbrica D., Tedeschi M., Venturino P. Low-dose glutathione administration in the prevention of cisplatin-induced peripheral neuropathy in rats. Neurotoxicology. 1994 Fall;15(3):701–704. [PubMed] [Google Scholar]
  69. Treskes M., van der Vijgh W. J. WR2721 as a modulator of cisplatin- and carboplatin-induced side effects in comparison with other chemoprotective agents: a molecular approach. Cancer Chemother Pharmacol. 1993;33(2):93–106. doi: 10.1007/BF00685326. [DOI] [PubMed] [Google Scholar]
  70. Von Hoff D. D., Schilsky R., Reichert C. M., Reddick R. L., Rozencweig M., Young R. C., Muggia F. M. Toxic effects of cis-dichlorodiammineplatinum(II) in man. Cancer Treat Rep. 1979 Sep-Oct;63(9-10):1527–1531. [PubMed] [Google Scholar]
  71. Walsh T. J., Clark A. W., Parhad I. M., Green W. R. Neurotoxic effects of cisplatin therapy. Arch Neurol. 1982 Nov;39(11):719–720. doi: 10.1001/archneur.1982.00510230045013. [DOI] [PubMed] [Google Scholar]
  72. Weinstein I. B. Relevance of cyclin D1 and other molecular markers to cancer chemoprevention. J Cell Biochem Suppl. 1996;25:23–28. [PubMed] [Google Scholar]
  73. Windebank A. J., Poduslo J. F. Neuronal growth factors produced by adult peripheral nerve after injury. Brain Res. 1986 Oct 15;385(1):197–200. doi: 10.1016/0006-8993(86)91567-2. [DOI] [PubMed] [Google Scholar]
  74. Windebank A. J., Smith A. G., Russell J. W. The effect of nerve growth factor, ciliary neurotrophic factor, and ACTH analogs on cisplatin neurotoxicity in vitro. Neurology. 1994 Mar;44(3 Pt 1):488–494. doi: 10.1212/wnl.44.3_part_1.488. [DOI] [PubMed] [Google Scholar]
  75. Zheng J. L., Stewart R. R., Gao W. Q. Neurotrophin-4/5 enhances survival of cultured spiral ganglion neurons and protects them from cisplatin neurotoxicity. J Neurosci. 1995 Jul;15(7 Pt 2):5079–5087. doi: 10.1523/JNEUROSCI.15-07-05079.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  76. Zheng J. L., Stewart R. R., Gao W. Q. Neurotrophin-4/5, brain-derived neurotrophic factor, and neurotrophin-3 promote survival of cultured vestibular ganglion neurons and protect them against neurotoxicity of ototoxins. J Neurobiol. 1995 Nov;28(3):330–340. doi: 10.1002/neu.480280306. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES